Business Wire

MANTIS

Share
MANTIS Startup to Disrupt Online Advertising Industry With Advanced Online Video Vetting AI Technology

Mantis-ai.com will launch its Artificial Intelligence (AI) tool for the first time, which will be available for advertisers during the #vivatech conference in Paris, May 2018 at startup booth: D17-001, Viva Technology Paris 24-26 May, 2018.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005610/en/

Over the past year, SMOs released several official reports surrounding decisions by the largest global advertisers to withdraw ad campaigns from the top four online video publishers, due to failures in online video content vetting and lack of advertiser control over ad placement within relevant content.

Mantis is a video moderation system that uses state-of-the-art AI techniques to identify video content that is relevant for advertisers through a highly efficient content vetting system. The Mantis vetting system detects, classifies and categorizes relevant content based on specified brand attributes and characteristics, ensuring brand safety and efficient spending of online advertising budgets.

Feras Maddah the CEO says, “Advertisers will now have the option of applying pressure on publishers to only place ads in videos that adhere to a brand’s specified ‘safe list.’ This new tool will allow advertisers to conduct online video campaigns more effectively and efficiently, securing brand perception associated with selected content. Within the next 3 months, ongoing trials will conclude and results of the trials will be published with full reports on Mantis’ performance.”

Dr. (PhD) Bernard Ghanem, the Project Director for Mantis says, “Mantis presents an innovative tool for the online advertising world. The system uses sophisticated AI techniques developed in-house to translate brand-safe attributes (similar to those found in an advertising campaign brief) into visual cues that can be very quickly found and recognized in a video. Mantis technology can be used by advertisers in two main ways: (1) to quickly earmark thousands of videos that follow brand specific attributes for ad placement or (2) to assess whether videos with ads already placed in them are coherent with these brand attributes.

Maddah adds, “Mantis will significantly help reduce wastage in advertising spending caused by ad spillovers onto irrelevant or brand-unsafe content and, in turn, improve budget allocation”.

Dr. Ghanem outlines two major benefits of Mantis, “First, Mantis can determine if an activity or cue in a video can be considered brand-safe or unsafe, and consequently, alert the advertiser to whether or not an ad should be placed in that specific video.

Second, Mantis is equipped with an added-value feature where ads can be placed at specific time intervals in a video based on its relevance and favorability to the brand. For example, Mantis can enable advertisers to embed banner ads for sportswear at the exact time a basketball dunk happens in a video across the publisher’s platform. Mantis does this by automatically detecting when that specific activity (basketball dunk) occurs in the video and earmarks it for ad placement.”

For more information, please visit:
http://mantis-ai.com/
http://www.mantis-ai.com/news
Twitter: @mantis_ai

*Source: AETOSWire

Contact:

Mantis
FERAS ALMADDAH, +966560690606
Chief Executive Officer
f.almaddah@mantis-ai.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye